Here are the 10-K annual reports from Teva Pharm Indus Ltd (TEVJF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TEVJF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEVJF filings page.
Teva Pharmaceutical Industries files its Annual Report on Form 10-K, outlining a global biopharmaceutical business built on generics, biosimilars and innovative medicines across three segments: United States, Europe and International Markets.
The company highlights key branded CNS products such as AUSTEDO, AJOVY, UZEDY and COPAXONE, plus oncology and respiratory franchises, while expanding a broad biosimilars portfolio through collaborations with Samsung Bioepis, Formycon, Prestige Biopharma and others. Teva reports a 2025 workforce of 33,950 employees in 57 countries and 1,149,812,898 ordinary shares outstanding as of December 31, 2025.
Management emphasizes its “Pivot to Growth” strategy, including focus on high-value and complex generics, divestiture of the API business, AI-driven efficiency initiatives, and continued network optimization. The filing also details extensive U.S., European and international regulatory frameworks, including the Inflation Reduction Act’s impact on AUSTEDO Medicare pricing from 2027 and Teva’s ongoing legal challenge to aspects of the program.